Review of Autism Profiles and Response to Sertraline in Fragile X Syndrome-Associated Autism vs. Non-syndromic Autism; Next Steps for Targeted Treatment
Authors:
Open Access
- 30 October 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 11, 581429
Abstract
Given significant genetic, molecular, and phenotypic overlaps, researchers have begun to investigate whether targeted treatments for Fragile X Syndrome (FXS) could also be beneficial for patients with Autism Spectrum Disorder (ASD). For example, low-dose sertraline, an SSRI, was used in two recent controlled trials in children with FXS and ASD. The first trial recruited 52 children with FXS, 32 of which were also diagnosed with ASD; the second trial recruited 58 children with non-syndromic ASD. One focus of the present study is to compare the response to sertraline between the FXS-associated ASD and non-syndromic ASD groups. Another focus is to compare baseline ASD-related characteristics between the groups and review these differences within the context of recent literature comparing these populations. Our comparison showed more severe ASD profiles in children with non-syndromic ASD vs. FXS-associated ASD. Regarding response to sertraline, the FXS-ASD group displayed significant improvements in language development, while the non-syndromic group did not show any significant improvements. One possible explanation for this differential response is the distinct anxiety profiles that are seen in these two groups. The heightened anxiety phenotype seen in those with FXS-ASD may have led to a greater relief of anxiety symptoms with sertraline compared to those with non-syndromic ASD; this, in turn, could have led to measurably greater developmental gains. Further research is required to solidify this connection between anxiety relief and developmental gains in these populations.Keywords
Funding Information
- Health Resources and Services Administration (R40MCH27701)
- National Institute of Child Health and Human Development (U54 HD079125)
This publication has 30 references indexed in Scilit:
- The trouble with spines in fragile X syndrome: density, maturity and plasticityNeuroscience, 2013
- Genome-wide Transcriptome Profiling Reveals the Functional Impact of Rare De Novo and Recurrent CNVs in Autism Spectrum DisordersThe American Journal of Human Genetics, 2012
- Sporadic autism exomes reveal a highly interconnected protein network of de novo mutationsNature, 2012
- De Novo Gene Disruptions in Children on the Autistic SpectrumNeuron, 2012
- Sertraline May Improve Language Developmental Trajectory in Young Children with Fragile X Syndrome: A Retrospective Chart ReviewAutism Research and Treatment, 2012
- Rare De Novo Variants Associated with Autism Implicate a Large Functional Network of Genes Involved in Formation and Function of SynapsesNeuron, 2011
- Targeted treatments for fragile X syndromeJournal of Neurodevelopmental Disorders, 2011
- Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down SyndromeThe Journal of Neuroscience, 2010
- Word learning in children with autism spectrum disorders.Developmental Psychology, 2009
- Recognizing and treating depression in children and adolescentsAmerican Journal of Health-System Pharmacy, 2006